Juniper Systems Celebrates Its 30th Anniversary
For 30 years Juniper Systems, Inc., has provided mobile workers with hassle-free data collection equipment
BIRMINGHAM, United Kingdom, May 15, 2023 (GLOBE NEWSWIRE) -- Today Juniper Systems, Inc., a manufacturer of ultra-rugged handheld computers and precision GNSS receivers, announced it is celebrating its 30th anniversary in business in 2023: 30 years of serving partners and customers with the best rugged data collection devices, agriculture research equipment, software and world-class customer service.
The company expressed its deep appreciation to their many partners and to those that help the company accomplish its goal every day to bring a hassle-free and personalised data collection experience to mobile workers around the world.
‘We’ve seen tremendous growth during these 30 years’, said Mr DeVon Labrum, president and CEO of Juniper Systems. ‘From our beginnings in agriculture research to our mobile computer business, we have always relied on great employees and strong and lasting partnerships with customers to achieve our success’.
The company was founded in 1993 under the name HarvestMaster and primarily served the agriculture research market with weigh systems and data-logging handheld computers. With the growth of the company's mobile computer business in other markets such as natural resources, forestry, and geospatial, the company was renamed Juniper Systems to reflect the broader industry base outside of agriculture. The HarvestMaster name has continued as a brand of Juniper Systems.
In addition to its headquarters in northern Utah, there are two locations in Europe: Juniper Systems Limited is based in the United Kingdom and serves the EMEA and India territories; and the HarvestMaster Europe office is located in Austria.
Juniper Systems has introduced dozens of highly-regarded and rugged field data collectors over its 30 years, with many products lasting more than ten years in the field. As Juniper has grown and expanded into new industries, so have its offerings. Key product lines in the company’s history include the Allegro™ and Archer™ handheld field computers, Geode™ GNSS receivers, and the Mesa® family of rugged tablets.
‘We have a legacy of releasing rugged devices that are rock solid and field ready and that last for years in the field’, Mr Labrum said. ‘Our communication with partners and end-users always inspires our next iteration of a product. We seek feedback from those who use our devices each day to ensure our current and future products meet their demands and withstand the rugged environments that they work in’.
As Juniper Systems celebrates 30 years in 2023, the company is looking forward to its next 30 years as it strives to grow lasting partnerships to help workers everywhere thrive.
About Juniper Systems Limited
Founded in 1993, Juniper Systems, Inc., (https://junipersys.com) is a world leader in the design and manufacture of ultra-rugged tablets, handheld computers, GPS receivers, mapping software and field computing solutions. Professionals utilise Juniper Systems’ innovative mobile computers in natural resources, utilities and public services, geospatial, industrial, mining, railway, and military markets. In addition, the company’s HarvestMaster brand makes solutions for agricultural applications.
Juniper Systems is based in Logan, UT, USA, and employs more than 190 people. It was twice recognised as one of the fastest-growing companies in the Beehive State and has been honored with awards for best compensation, work-life balance, and employee happiness among small and mid-sized U.S. companies.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b1b8cd3c-d226-48e2-b73e-79cc2d5b881a
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Grant of Restricted Stock Units and Warrants to Employees in Genmab8.6.2023 23:22:17 CEST | Press release
Company Announcement COPENHAGEN, Denmark; June 8, 2023 –Genmab A/S (Nasdaq:GMAB) announced todaythat the Board decided to grant 7,825 restricted stock units and 8,106 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,688. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the Board of Directors. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Governance > Compensation > Restricted Stock Units. The exercise price fo
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants8.6.2023 23:19:00 CEST | Press release
FDA Advisory Committee unanimously recommendsnirsevimab as first immunization against RSV disease forall infants Nirsevimab would be the first immunization specifically designed to protect all infants through their first RSV season, if approvedAcross all clinical trials, a single dose of nirsevimab delivered high, consistent and sustained efficacy and favorable safety against RSV diseaseThe FDA has indicated it will work to expedite its review; Sanofi remains committed to delivering nirsevimab in time for the 2023-2024 RSV season Paris, June 8, 2023. The U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously 21 to 0 that Sanofi and AstraZeneca’s nirsevimab has a favorable benefit risk profile for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season. The Committee also voted 19 to 2 in support of nirsevimab’s favorable benefit ris
DBV Technologies to Participate in Upcoming EAACI Congress 20238.6.2023 22:30:00 CEST | Press release
Montrouge, France, June 8, 2023 DBV Technologies to Participate in Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress, June 9 – 11, 2023, in Hamburg, Germany. DBV will present three posters and will also host a symposium and exhibit booth in the EAACI exhibit hall. Data to be presented during the scientific sessions will describe the current burden of peanut allergy and treatment management strategies for children in the U.K. DBV will also present data from its completed EPITOPE Phase 3 study assessing the efficacy and safety of epicutaneous immunotherapy (EPIT) using Viaskin Peanut™ in toddlers aged 1-3 years with or without concomitant asthma. The toddler age-group represents the age range in which many peanut-allergic children are diagnosed, yet there are currently n
GOGL - Transactions made under the buy-back program8.6.2023 22:30:00 CEST | Press release
Reference is made to the stock announcement on October 4, 2022, where Golden Ocean Group Limited (OSE/NASDAQ: GOGL) announced the commencement of its share buy-back program of maximum USD 100 million to purchase up to an aggregate of 10,000,000 of the company's common shares in a 12-month period from the announcement. Golden Ocean Group Limited (“GOGL” or the “Company”) announces that the Company has during the week ending Friday June 2, 2023, purchased 25,343 of the Company’s own common stocks. 343 of the shares have been bought on the Oslo Stock Exchange at an average price of NOK 80.00 per share and 25,000 of the shares have been bought on Nasdaq at an average price of USD 7.19 per share. Following the completion of the above transactions, GOGL owns a total of 952,428 of own shares, corresponding to 0.47% of the Company’s share capital. An overview of all transactions made under the buy-back program that have been carried out during the above-mentioned date is attached to this repor
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants8.6.2023 22:00:00 CEST | Press release
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 36,006 divided into 36,006 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are